<DOC>
	<DOCNO>NCT01539681</DOCNO>
	<brief_summary>Prospective , non-interventional , multi-center study . Patients affect Hepatocellular Carcinoma ( HCC ) candidate systemic therapy decision treat sorafenib make . Aim non-interventional , post-marketing study evaluate efficacy sorafenib term overall survival rate 12 month patient HCC daily-life treatment condition .</brief_summary>
	<brief_title>Sorafenib Hepatocellular Carcinoma Clinical Practice Italy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients histologically/cytologically confirm HCC radiographically diagnose per AASLD criterion , candidate systemic therapy decision treat sorafenib make Patients must sign informed consent form Patients must life expectancy least 8 week Inclusion criterion must follow approve local product information . Prior treatment sorafenib Concomitant participation clinical study Exclusion criterion must follow approve local product information .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Cancer , Liver</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
</DOC>